---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001098"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:33:25.095670+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4

## Summary
- Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.
- Phase 2 prurigo nodularis and atopic dermatitis studies fully enrolled; data expected summer and late 2026.
- Phase 1 CDX-622 (bispecific SCF & TSLP) proof-of-mechanism study in mild-to-moderate asthma initiated.
- Q4 2025 net loss $81.3M ($1.22 per share) vs $47.1M ($0.71) year ago; R&D spend rose to $75.3M.
- Cash, cash equivalents and marketable securities $518.6M at Dec 31, 2025; runway through 2027.

## SEC filing metadata
- accession: 0001171843-26-001098
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184326001098/0001171843-26-001098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184326001098/f8k_022526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001098
- JSON: https://secwatch.observer/filing/0001171843-26-001098.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.